How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

21,953 results for

Breast Cancer Diagnosis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines

Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer (...) : Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Last updated: June 11, 2019 Project Number: RB1351-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of 3D digital tomosynthesis with or without 2D mammography compared with 2D mammography alone for breast cancer diagnosis? What is the diagnostic accuracy of 3D digital tomosynthesis with or without 2D mammography compared with 2D mammography alone

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

2. Telemammography for Breast Cancer Diagnosis: Clinical Utility, Cost-Effectiveness, and Guidelines

Telemammography for Breast Cancer Diagnosis: Clinical Utility, Cost-Effectiveness, and Guidelines Telemammography for Breast Cancer Diagnosis: Clinical Utility, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Telemammography for Breast Cancer Diagnosis: Clinical Utility, Cost-Effectiveness, and Guidelines Telemammography for Breast Cancer Diagnosis: Clinical Utility, Cost-Effectiveness, and Guidelines Last updated: August 27, 2019 Project Number: RB1389-000 Product (...) Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical utility of telemammography for the diagnosis of breast cancer? What is the cost-effectiveness of telemammography for the diagnosis of breast cancer? What are the evidence based guidelines regarding the use of telemammography for the diagnosis of breast cancer? Key Message No relevant health technology assessments, systematic reviews, meta-analyses, randomized-controlled

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

3. Digital breast tomosynthesis for breast cancer diagnosis and screening

Digital breast tomosynthesis for breast cancer diagnosis and screening Digital breast tomosynthesis for breast cancer diagnosis and screening Digital breast tomosynthesis for breast cancer diagnosis and screening HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Digital breast tomosynthesis for breast cancer diagnosis and screening. Lansdale (...) , particularly when compared with modifications of digital mammography that involve spot compression and magnified and angled views. Key Questions: Does digital breast tomosynthesis (DBT) provide a more accurate diagnosis than conventional mammography in women with symptoms or suspicious breast lesions? Does DBT reduce the recall and biopsy rates and the rates of breast cancer morbidity and mortality in asymptomatic women who undergo routine screening with this test? Does information obtained with DBT

2017 Health Technology Assessment (HTA) Database.

4. Modifiable patient-related barriers and their association with breast cancer detection practices among Ugandan women without a diagnosis of breast cancer. (PubMed)

Modifiable patient-related barriers and their association with breast cancer detection practices among Ugandan women without a diagnosis of breast cancer. Most women with breast cancer in sub-Saharan Africa (SSA) are diagnosed with late-staged disease. The current study assesses patient-related barriers among women from a general SSA population to better understand how patient-related barriers contribute to diagnostic delays. Using convenience-based sampling, 401 Ugandan women without breast (...) cancer were surveyed to determine how prior participation in cancer detection practices correlate with patient-related barriers to prompt diagnosis. In a predominantly poor (76%) and rural population (75%), the median age of the participants was 38. Of the women surveyed, 155 (46%) had prior exposure to breast cancer education, 92 (27%) performed breast self-examination (BSE) and 68 (20%) had undergone a recent clinical breast examination (CBE), breast ultrasound or breast biopsy. The most commonly

Full Text available with Trip Pro

2019 PLoS ONE

5. Risks and benefits of HRT before and after a breast cancer diagnosis

Risks and benefits of HRT before and after a breast cancer diagnosis Risks and Benefits of HRT before and after a Breast Cancer Diagnosis | British Menopause Society Search for: Summary consensus statement Risks and Benefits of HRT before and after a Breast Cancer Diagnosis Risks and Benefits of HRT before and after a Breast Cancer Diagnosis 2018-11-28T11:58:36+01:00 Summary In women with a low underlying risk of breast cancer (i.e. most of the population): The benefits of HRT in the short-term (...) (up to 5 years’ use) for symptom relief will exceed potential harm The risk of breast cancer diagnosis associated with HRT is equivalent to, or less that of other lifestyle risk factors for breast cancer Communicating risk in terms of absolute excess risk with framing, minimizes bias and misinterpretation The potential risk of breast cancer diagnosis associated with unopposed or combined HRT should not be discussed in isolation of its other short and long-term benefits and risks In women at high

2018 British Menopause Society

6. The diagnosis of the menopause and management of oestrogen deficiency symptoms and arthralgia in women treated for breast cancer

The diagnosis of the menopause and management of oestrogen deficiency symptoms and arthralgia in women treated for breast cancer The diagnosis of the menopause and management of oestrogen deficiency symptoms and arthralgia in women treated for breast cancer | British Menopause Society Search for: Summary consensus statement The diagnosis of the menopause and management of oestrogen deficiency symptoms and arthralgia in women treated for breast cancer The diagnosis of the menopause and management (...) of oestrogen deficiency symptoms and arthralgia in women treated for breast cancer 2018-12-05T16:45:20+01:00 Key points An early menopause, estrogen deficiency symptoms and arthralgia are common side effects of systemic breast cancer therapies. Symptoms may persist for the duration of treatment and in some cases continue after treatment completion. The NICE Menopause Guidance [NG23] recommends referral of women to a healthcare professional with expertise in gynaecological endocrinology for counselling about

2018 British Menopause Society

7. Disparities in breast screening, stage at diagnosis, cancer treatment and the subsequent risk of cancer death: a retrospective, matched cohort of aboriginal and non-aboriginal women with breast cancer. (PubMed)

Disparities in breast screening, stage at diagnosis, cancer treatment and the subsequent risk of cancer death: a retrospective, matched cohort of aboriginal and non-aboriginal women with breast cancer. Australia's Aboriginal and Torres Strait Islander women have poorer survival and twice the disease burden from breast cancer compared to other Australian women. These disparities are influenced, but not fully explained, by more diagnoses at later stages. Incorporating breast screening, hospital (...) ; then assess the relationship between screening, treatment and the subsequent risk of breast cancer death.Breast cancers registered among Aboriginal women in South Australia in 1990-2010 (N = 77) were matched with a random selection of non-Aboriginal women by birth and diagnostic year, then linked to screening records, and treatment 2 months before and 13 months after diagnosis. Competing risk regression summarised associations of Aboriginality, breast screening, cancer stage and treatment with risk

2019 BMC health services research

8. Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast (PubMed)

Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Purpose The aim of this official guideline coordinated and published by the German Society for Gynecology and Obstetrics (DGGG) and the German Cancer Society (DKG) was to optimize the screening, diagnosis, therapy and follow-up care of breast (...) and statements which were modified and graded in a structured consensus procedure. Recommendations Part 1 of this short version of the guideline presents recommendations for the screening, diagnosis and follow-up care of breast cancer. The importance of mammography for screening is confirmed in this updated version of the guideline and forms the basis for all screening. In addition to the conventional methods used to diagnose breast cancer, computed tomography (CT) is recommended for staging in women

Full Text available with Trip Pro

2018 Geburtshilfe Und Frauenheilkunde

9. Digital breast tomosynthesis for breast cancer diagnosis and screening

Digital breast tomosynthesis for breast cancer diagnosis and screening Digital breast tomosynthesis for breast cancer diagnosis and screening Digital breast tomosynthesis for breast cancer diagnosis and screening HAYES, Inc. Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc.. Digital breast tomosynthesis for breast cancer diagnosis and screening (...) . Lansdale: HAYES, Inc.. Directory Publication. 2015 Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Breast Neoplasms; Humans; Mammography; Public Health; Tomography, X-Ray Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo

2015 Health Technology Assessment (HTA) Database.

10. Body mass index and prognosis of breast cancer: An analysis by menstruation status when breast cancer diagnosis. (PubMed)

Body mass index and prognosis of breast cancer: An analysis by menstruation status when breast cancer diagnosis. To examine whether obesity/overweight is a risk predictor for breast cancer recurrence and death by menopausal status in a retrospective study.We performed a retrospective analysis of 1017 breast cancer patients treated in our hospital from January 2004 to December 2012. Three groups were divided according to body mass index (BMI) when breast cancer diagnosis: normal weight, BMI (...)  < 25.0 kg/m; overweight, 25.0≤BMI < 30.0 kg/m; and obesity, BMI≥30.0 kg/m. The clinicopathological characteristics and clinical outcomes of patients within 5 years following breast cancer diagnosed were analyzed. Subgroup analyses of BMI on breast cancer prognosis were analyzed according to the menopausal status when breast cancer diagnosis. The Cox proportional hazards model was used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs).Overweight and obesity groups were associated

Full Text available with Trip Pro

2018 Medicine

11. Dietary changes in the first 3 years after breast cancer diagnosis: a prospective Chinese breast cancer cohort study (PubMed)

Dietary changes in the first 3 years after breast cancer diagnosis: a prospective Chinese breast cancer cohort study The diagnosis of cancer can motivate patients to change their dietary habits. Evidence on changes in dietary intake before and after breast cancer diagnosis in Chinese women has been limited.In an ongoing prospective cohort study which involved 1,462 Chinese women with early-stage breast cancer, validated food frequency questionnaire was used to assess prediagnostic dietary (...) intake (using questionnaire to recall dietary intake before diagnosis, which completed at baseline, ie, 0-12 months after diagnosis) and postdiagnostic dietary intake at 18-month and 36-month follow-ups after diagnosis. This study quantitatively compared dietary intake across three time points before and after breast cancer diagnosis.Breast cancer patients significantly and continuously increased vegetables and fruits consumption, from 4.54 servings/day at prediagnosis to 5.19 and 5.59 servings/day

Full Text available with Trip Pro

2018 Cancer management and research

12. APC gene promoter aberrant methylation in serum as a biomarker for breast cancer diagnosis: A meta-analysis. (PubMed)

APC gene promoter aberrant methylation in serum as a biomarker for breast cancer diagnosis: A meta-analysis. The aim of this study was to evaluate the clinical efficacy of APC gene promoter methylation in serum as a biomarker for breast cancer (BC) diagnosis.Two reviewers systematically searched online resources to identify the publications relevant to APC gene promoter methylation and BC. The data of true positive, false positive, false negative, and true negative were extracted from each (...) ), 4.58 (95% CI 1.85-11.37) and 0.80, respectively. A Deeks' funnel plot and Egger's line regression test (t = 1.43, P = 0.18) indicated no publication bias was present.Because of low sensitivity, APC gene promoter methylation in serum was not suitable for BC screening. However, as specificity was very high, detection of serum APC gene promoter methylation could be used as tool to confirm BC.© 2018 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

Full Text available with Trip Pro

2018 Thoracic cancer

13. Change in longitudinal trends in sleep quality and duration following breast cancer diagnosis: results from the Women’s Health Initiative (PubMed)

Change in longitudinal trends in sleep quality and duration following breast cancer diagnosis: results from the Women’s Health Initiative Breast cancer survivors frequently report sleep problems, but little research has studied sleep patterns longitudinally. We examined trends in sleep quality and duration up to 15 years before and 20 years after a diagnosis of breast cancer, over time among postmenopausal women participating in the Women's Health Initiative (WHI). We included 12,098 (...) participants who developed invasive breast cancer after study enrollment. A linear mixed-effects model was used to determine whether the time trend in sleep quality, as measured by the WHI Insomnia Rating Scale (WHIIRS), a measure of perceived insomnia symptoms from the past 4 weeks, changed following a cancer diagnosis. To examine sleep duration, we fit a logistic regression model with random effects for both short (<6 h) and long (≥9 h) sleep. In addition, we studied the association between depressive

Full Text available with Trip Pro

2018 NPJ breast cancer

14. Reclassification of breast cancer: Towards improved diagnosis and outcome. (PubMed)

Reclassification of breast cancer: Towards improved diagnosis and outcome. The subtyping of breast cancer based on features of tumour biology such as hormonal receptor and HER2 status has led to increasingly patient-specific treatment and thus improved outcomes. However, such subgroups may not be sufficiently informed to best predict outcome and/or treatment response. The incorporation of multi-modal data may identify unexpected and actionable subgroups to enhance disease understanding (...) and improve outcomes.This retrospective cross-sectional study used the cancer registry Surveillance, Epidemiology and End Results (SEER), which represents 28% of the U.S. population. We included adult female patients diagnosed with breast cancer in 2010. Latent class analysis (LCA), a data-driven technique, was used to identify clinically homogeneous subgroups ("endophenotypes") of breast cancer from receptor status (hormonal receptor and HER2), clinical, and demographic data and each subgroup

Full Text available with Trip Pro

2019 PLoS ONE

15. Prostate cancer: diagnosis and management

bicalutamide monotherapy (longer than 6 months), offer prophylactic radiotherapy to both breast buds within the first month of treatment. Use a single fraction of 8 Gy using orthovoltage, or electron beam radiotherapy. [2008] [2008] 1.4.17 If radiotherapy does not prevent gynaecomastia, consider weekly tamoxifen [5] . [2008] [2008] F Fatigue atigue 1.4.18 T ell people who are starting androgen deprivation therapy that fatigue is a Prostate cancer: diagnosis and management (NG131) © NICE 2019. All rights (...) Prostate cancer: diagnosis and management Prostate cancer: diagnosis and Prostate cancer: diagnosis and management management NICE guideline Published: 9 May 2019 www.nice.org.uk/guidance/ng131 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

16. Breast surgery for metastatic breast cancer. (PubMed)

2016. We also searched ClinicalTrials.gov (22 February 2016) and the WHO International Clinical Trials Registry Platform (24 February 2016). We conducted an additional search in the American Society of Clinical Oncology (ASCO) conference proceedings in July 2016 that included reference checking, citation searching, and contacting study authors to identify additional studies.The inclusion criteria were randomised controlled trials of women with metastatic breast cancer at initial diagnosis comparing (...) Breast surgery for metastatic breast cancer. Metastatic breast cancer is not a curable disease, but women with metastatic disease are living longer. Surgery to remove the primary tumour is associated with an increased survival in other types of metastatic cancer. Breast surgery is not standard treatment for metastatic disease, however several recent retrospective studies have suggested that breast surgery could increase the women's survival. These studies have methodological limitations

2018 Cochrane

17. Hereditary Cancer Syndromes-A Primer on Diagnosis and Management: Part 1: Breast-Ovarian Cancer Syndromes. (PubMed)

Hereditary Cancer Syndromes-A Primer on Diagnosis and Management: Part 1: Breast-Ovarian Cancer Syndromes. Cancer is the second leading cause of death in both men and women in the United States, with colorectal cancer and breast cancer being two of the most frequent cancer types. Hereditary causes occurring due to pathogenic sequence variants and defects in certain genes makes up roughly 5% of all colorectal cancers and breast-ovarian cancers. High-risk hereditary predisposition syndromes have (...) been associated with a substantially increased lifetime risk for the development of colorectal cancers and breast-ovarian cancers depending on the genetic syndrome, and many people also carry an increased risk of several other cancers compared with the general population. The aim of this review was to provide comprehensive literature on the most commonly encountered hereditary predisposition syndromes, including Lynch syndrome, familial adenomatous polyposis, MUTYH-associated polyposis

2019 Mayo Clinic Proceedings

18. Use of Digital Breast Tomosynthesis with Mammography for Breast Cancer Screening or Diagnosis

Use of Digital Breast Tomosynthesis with Mammography for Breast Cancer Screening or Diagnosis Use of digital breast tomosynthesis with mammography for breast cancer screening or diagnosis Use of digital breast tomosynthesis with mammography for breast cancer screening or diagnosis BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation (...) BlueCross BlueShield Association. Use of digital breast tomosynthesis with mammography for breast cancer screening or diagnosis. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 28(6). 2014 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Breast Neoplasmss; Imaging, Three-Dimensional; Mammography; Mass Screening Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence

2014 Health Technology Assessment (HTA) Database.

19. Digital breast tomosynthesis for breast cancer diagnosis and screening

Digital breast tomosynthesis for breast cancer diagnosis and screening Digital breast tomosynthesis for breast cancer diagnosis and screening Digital breast tomosynthesis for breast cancer diagnosis and screening Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Digital breast tomosynthesis for breast cancer diagnosis and screening. Lansdale: HAYES, Inc (...) .. Directory Publication. 2014 Timeliness warning This report has been archived and may contain outdated information. To request a copy of the report please contact the organisation directly. Final publication URL The report may be purchased from: Indexing Status Subject indexing assigned by CRD MeSH Breast Neoplasms; Early Detection of Cancer; Females; Imaging, Three-Dimensional; Mammography; Mass Screening; Radiographic Image Enhancement; Safety; Sensitivity and Specificity; Tomography, X-Ray Computed

2014 Health Technology Assessment (HTA) Database.

20. Digital breast tomosynthesis for breast cancer screening and diagnosis in women with dense breasts - a systematic review and meta-analysis. (PubMed)

Digital breast tomosynthesis for breast cancer screening and diagnosis in women with dense breasts - a systematic review and meta-analysis. This study aimed to systematically review and to meta-analyse the accuracy of digital breast tomosynthesis (DBT) versus digital mammography (DM) in women with mammographically dense breasts in screening and diagnosis.Two independent reviewers identified screening or diagnostic studies reporting at least one of four outcomes (cancer detection rate-CDR (...) , recall rate, sensitivity and specificity) for DBT and DM in women with mammographically dense breasts. Study quality was assessed using QUADAS-2. Meta-analysis of CDR and recall rate used a random effects model. Summary ROC curve summarized sensitivity and specificity.Sixteen studies were included (five diagnostic; eleven screening). In diagnosis, DBT increased sensitivity (84%-90%) versus DM alone (69%-86%) but not specificity. DBT improved CDR versus DM alone (RR: 1.16, 95% CI 1.02-1.31

Full Text available with Trip Pro

2018 BMC Cancer

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>